Severe Rhabdomyolysis Associated with Simvastatin and Role of Ciprofloxacin and Amlodipine Coadministration

De Schryver, Nicolas;Wittebole, Xavier;Van den Bergh, Peter;Haufroid, Vincent;Hantson, Philippe;et.al.
(2015) Case Reports in Nephrology — Vol. 2015, p. 761393 [1-4] (2015)

Files

DeSchryveretalSevereRhabdomyolysisAssociatedwithSimvastatinandRoleofCaseReportsinNephrology2015.pdf
  • Open Access
  • Adobe PDF
  • 476.13 KB
Download

Details

Authors
Show more
Abstract
(en) Simvastatin is among the most commonly used prescription medications for cholesterol reduction and the most common statin-related adverse drug reaction is skeletal muscle toxicity. Multiple factors have been shown to influence simvastatin-induced myopathy. In addition to age, gender, ethnicity, genetic predisposition, and dose, drug-drug interactions play a major role. This is particularly true for drugs that are extensively metabolized by cytochrome P450 (CYP)3A4. We describe a particularly severe case of rhabdomyolysis after the introduction of ciprofloxacin, a weak CYP3A4 inhibitor, in a patient who previously tolerated the simvastatin-amlodipine combination
Affiliations

Citations

  • APA
  • Chicago
  • FWB

De Schryver, N., Wittebole, X., Van den Bergh, P., Haufroid, V., Goffin, E., & Hantson, P. (2015). Severe Rhabdomyolysis Associated with Simvastatin and Role of Ciprofloxacin and Amlodipine Coadministration. Case Reports in Nephrology, 2015, 761393 [1-4]. https://doi.org/10.1155/2015/761393 (Original work published 2015)